Imiquimod: A review

Journal of Cutaneous Medicine and Surgery

Volumn 6, Issue 6, 2002, Pages 554-560

  Gupta, Aditya K ^a,b   Browne, Melanie ^a   Bluhm, Robyn ^a  

^a Mediprobe Laboratories Inc   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMIQUIMOD;

ACTINIC KERATOSIS; ADULT; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BASAL CELL CARCINOMA; BOWEN DISEASE; CARCINOMA IN SITU; CELLULAR IMMUNITY; CONDYLOMA; CYTOKINE PRODUCTION; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; ERYTHEMA; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; MOLLUSCUM CONTAGIOSUM; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; SKIN ULCER; SQUAMOUS CELL CARCINOMA; VULVA CARCINOMA IN SITU;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AMINOQUINOLINES; CONDYLOMATA ACUMINATA; HUMANS; OINTMENTS;

EID: 0036873547     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-001-0134-6     Document Type: Review

References (51)

1. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000; 43:S6-S11.
2. Wolverton SE (2001) Comprehensive Dermatologic Drug Theraphy. W.B. Saunders, Philadephia, pp 529.
3. (2000) Physician's Desk Reference 54th ed. Medical Economic Company Inc., Monwale, NJ.
4. Miller RL, Gerster JF, Owens ML, et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999; 21:1-14.
5. Dahl MV. Imiquimod: an immune response modifier. J Am Acad Dermatol 2000; 43:S1-S5.
6. Imbertson LM, Beaurline JM, Couture AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998; 110:734-739.
7. (2001) Compendium of Pharmaceuticals and Specialties, 36th ed. Canadian Pharmacists Association, Toronto, Ontario.
8. Cutler K, Kagen MH, Don PC, et al. Treatment of facial verrucae with topical imiquimod cream in a patient with human immuno-deficiency virus. Acta Derm Venereol 2000; 80:134-135.
9. Skinner RB, Ray S, Talanin NY. Treatment of molluscum contagiosum with topical 5% imiquimod cream. Pediatr Dermatol 2000; 17:420.
10. Liota E, Smith KJ, Buckley R, et al. Imiquimod therapy for molluscum contagiosum. J Cutan Med Surg 2000; 4:76-82.
11. Barba AR, Kapoor S, Berman B. An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. Dermatol Online 2001; 7:20-26.
12. Koutsy LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1983; 10:122-163.
13. Tyring SK, Arany I, Stanley MA, et al. A randomized, controlled, molecular study of condylomata acuminata and clearance during treatment with imiquimod. J Infect Dis 1998; 178:511-555.
14. Syed TA, Hadi SM, Qureshi A, et al. Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study. J Infect 2000; 41:148-151.
15. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998; 134:25-30.
16. Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod) J Am Acad Dermatol 1998; 38:230-239.
17. Beutner KR, Tyring SK, Trofatter KF, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998; 42:789-794.
18. Fife KH, Ferenczy A, Douglas JM. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily or three times a day. Sex Transm Dis 2001; 28:226-231.
19. Gollnick H, Barasso R, Jappe U, et al. Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS 2001; 12:22-28.
20. Wagman FA, Estape RE, Angioli R, et al. Self-administered topical 5% imiquimod cream for external anogenital warts in adolescent girls. Obset Gynecol 2001; 97:S14.
21. Gilson RJ, Shupack JL, Friedman-Kien AE, et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS 1999; 13:2397-2404.
22. Eggleton S, Tang A. Management of difficult anogenital warts. Sex Transm Infect 1999; 75:449-450.
23. Moore RA, Edwards JE, Hopwood J, et al. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis 2001; 1:3-16.
24. Freedberg IM, Eisen AZ, Wolff K, et al. Fitzpatrick's Dermatology in General Medicine, 5th ed. McGraw-Hill, New York pp 1371.
25. Davis G, Wentworth J, Richard J, Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia: a report of four cases. J Reprod Med 2000; 45:619-623.
26. Stockfleth E, Rowert J, Arndt R, et al. Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis. Br J Dermatol 2000; 143:846-850.
27. Rinne D, Linhart C, Schofer H. Lip papillomatosis in immuno-deficiency: therapy with imiquimod. Br J Dermatol 2000; 142:196-197.
28. Schwab RA, Elson DM. Topical imiquimod for recalcitrant facial flat warts. Cutis 2000; 65:160-162.
29. Weisshaar E, Gollnick H. Potentiating effect of imiquimod in the treatment of verrucae vulgares in immunocompromised patients. Acta Derm Venereol 2000; 80:306-307.
30. Hengge UR, Esser S, Schultewolter T, et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000; 143:1026-1031.
31. Oster-Schmidt C. Imiquimod: a new possibility for treatment-resistant verrucae planae. Arch Dermatol 2001; 137:666-667.
32. Weinberg JM, Stewart A, Stern JO. Successful treatment of extensive condyloma acuminata of the inguinal area and thigh with topical imiquimod cream. Acta Derm Venereol 2001; 81:76-77.
33. Harrison CJ, Jenski L, Voychehovski T, et al. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res 1998; 10:209-224.
34. Christensen B, Hengge UR. Recurrent urogenital herpes simplex -successful treatment with imiquimod? Sex Transm Infect 1999; 75:132-133.
35. Brown CW, O'Donoghue M, Moore J, et al. Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical imiquimod. Cutis 2000; 65:363-366.
36. Buckley R, Smith K. Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease. Arch Dermatol 1999; 135:1167-1169.
37. Strauss RM, Doyle EL, Mohsen AH, et al. Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient. Int J STD AIDS 2001; 12:264-266.
38. Syed TA, Goswami J, Ahmadpour OA, et al. Treatment of molluscum contagiosum in males within an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. J Dermatol 1998; 25:309-313.
39. Edwards L, Owens ML, Andres KL, et al. (2000) A pilot study evaluating imiquimod 5% cream versus vehicle in the treatment of actinic keratoses. Poster presented at the 58th Annual Meeting of the American Academy of Dermatology.
40. Stockfleth E, Meyer T, Bennignhoff B, et al. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001; 144:1050-1053.
41. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41:1002-1007.
42. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44:807-813.
43. Hannuksela-Svahn A, Nordal E. Treatment of multiple basal cell carcinomas in the scalp with imiquimod 5% cream. Acta Derm Venereol 2000; 80:381-399.
44. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg 2000; 26:577-578.
45. Pehoushek J, Smith KJ. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch Dermatol 2001; 137:14-16.
46. Hengge UR, Stark R. Topical imiquimod to treat intraepidermal carcinoma. Arch Dermatol 2001; 137:709-711.
47. Mackenzie-Wood A, Kossard S, de Launey J, et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44:462-470.
48. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001; 27:561-564.
49. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy. Dermatol Surg 2001; 27:143-146.
50. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000; 143:843-845.
51. Steinmann A, Funk JO, Schuler G, et al. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000; 43:555-556.